

Cite as: J. S. Gootenberg *et al.*,
Science 10.1126/science.aam9321
 (2017).

Nucleic acid detection with CRISPR-Cas13a/C2c2

Jonathan S. Gootenberg,^{1,2,3,4,5*} Omar O. Abudayyeh,^{1,2,3,4,6*} Jeong Wook Lee,⁷ Patrick Essletzbichler,^{1,2,3,4} Aaron J. Dy,^{1,4,8} Julia Joung,^{1,2,3,4} Vanessa Verdine,^{1,2,3,4} Nina Donghia,⁷ Nichole M. Daringer,⁸ Catherine A. Freije,^{1,11} Cameron Myhrvold,^{1,11} Roby P. Bhattacharyya,¹ Jonathan Livny,¹ Aviv Regev,^{1,9} Eugene V. Koonin,¹⁰ Deborah T. Hung,¹ Pardis C. Sabeti,^{1,11,12,13} James J. Collins,^{1,4,6,7,8†} Feng Zhang^{1,2,3,4†}

¹Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. ²McGovern Institute for Brain Research at MIT, Cambridge, MA 02139, USA. ³Department of Brain and Cognitive Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. ⁴Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. ⁵Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA. ⁶Department of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. ⁷Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA. ⁸Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. ⁹Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. ¹⁰National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD 20894, USA. ¹¹Center for Systems Biology, Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, MA 02138, USA. ¹²Department of Immunology and Infectious Disease, Harvard School of Public Health, Boston, MA 02115, USA. ¹³Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.

*These authors contributed equally to this work.

†Corresponding author. Email: zhang@broadinstitute.org (F.Z.); jimjc@mit.edu (J.J.C.)

Rapid, inexpensive, and sensitive nucleic acid detection may aid point-of-care pathogen detection, genotyping, and disease monitoring. The RNA-guided, RNA-targeting CRISPR effector Cas13a (previously known as C2c2) exhibits a “collateral effect” of promiscuous RNase activity upon target recognition. We combine the collateral effect of Cas13a with isothermal amplification to establish a CRISPR-based diagnostic (CRISPR-Dx), providing rapid DNA or RNA detection with attomolar sensitivity and single-base mismatch specificity. We use this Cas13a-based molecular detection platform, termed SHERLOCK (Specific High Sensitivity Enzymatic Reporter UnLOCKing), to detect specific strains of Zika and Dengue virus, distinguish pathogenic bacteria, genotype human DNA, and identify cell-free tumor DNA mutations. Furthermore, SHERLOCK reaction reagents can be lyophilized for cold-chain independence and long-term storage, and readily reconstituted on paper for field applications.

The ability to rapidly detect nucleic acids with high sensitivity and single-base specificity on a portable platform may aid in disease diagnosis and monitoring, epidemiology, and general laboratory tasks. Although methods exist for detecting nucleic acids (1–6), they have trade-offs among sensitivity, specificity, simplicity, cost, and speed. Microbial Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated (CRISPR-Cas) adaptive immune systems contain programmable endonucleases that can be leveraged for CRISPR-based diagnostics (CRISPR-Dx). While some Cas enzymes target DNA (7, 8), single effector RNA-guided RNases, such as Cas13a (previously known as C2c2) (8), can be reprogrammed with CRISPR RNAs (crRNAs) to provide a platform for specific RNA sensing (9–12). Upon recognition of its RNA target, activated Cas13a engages in “collateral” cleavage of nearby non-targeted RNAs (10). This crRNA-programmed collateral cleavage activity allows Cas13a to detect the presence of a specific RNA in vivo by triggering programmed cell death (10) or in vitro by nonspecific degradation of labeled RNA (10, 12). Here we describe SHERLOCK (Specific High Sensitivity Enzymatic Reporter UnLOCKing), an in vitro

nucleic acid detection platform with attomolar sensitivity based on nucleic acid amplification and Cas13a-mediated collateral cleavage of a reporter RNA (12), allowing for real-time detection of the target (Fig. 1A).

To achieve robust signal detection, we identified an ortholog of Cas13a from *Leptotrichia wadei* (LwCas13a), which displays greater RNA-guided RNase activity relative to *Leptotrichia shahii* Cas13a (LshCas13a) (10) (fig. S1). LwCas13a incubated with ssRNA target 1 (ssRNA 1), crRNA, and reporter (quenched fluorescent RNA) (Fig. 1B) (13) yielded a detection sensitivity of ~50 fM (Fig. 1C and fig. S2). Although this sensitivity is an improvement on previous studies with LbCas13a (12), attomolar sensitivity is required for many diagnostic applications (14–16). We therefore explored combining Cas13a-based detection with different isothermal amplification steps (figs. S3 and S4A) (17, 18). Of the methods explored, recombinase polymerase amplification (RPA) (18) afforded the greatest sensitivity and can be coupled with T7 transcription to convert amplified DNA to RNA for subsequent detection by LwCas13a. We refer to this combination of amplification by RPA, T7 RNA polymerase transcription of amplified DNA to RNA, and detection of

target RNA by Cas13a collateral RNA cleavage-mediated release of reporter signal as SHERLOCK.

We first determined the sensitivity of SHERLOCK for detection of RNA (when coupled with reverse transcription) or DNA targets. We achieved single molecule sensitivity for both RNA and DNA, as verified by digital-droplet PCR (ddPCR) (Fig. 1, C and D, and fig. S4, B and C). Attomolar sensitivity was maintained when we combined all SHERLOCK components in a single reaction, demonstrating the viability of this platform as a point-of-care (POC) diagnostic (fig. S4D). SHERLOCK has similar levels of sensitivity as ddPCR and quantitative PCR (qPCR), two established sensitive nucleic acid detection approaches, whereas RPA alone was not sensitive enough to detect low levels of target (fig. S5, A to D). Moreover, SHERLOCK shows less variation than ddPCR, qPCR, and RPA, as measured by the coefficient of variation across replicates (fig. S5, E and F).

We next examined whether SHERLOCK would be effective in infectious disease applications that require high sensitivity. We produced lentiviruses harboring genome fragments of either Zika virus (ZIKV) or the related flavivirus Dengue (DENV) (19) (Fig. 2A). SHERLOCK detected viral particles down to 2 aM and could discriminate between ZIKV and DENV (Fig. 2B). To explore the potential use of SHERLOCK in the field with paper-spotting and lyophilization (1), we first demonstrated that Cas13a-crRNA complexes lyophilized and subsequently rehydrated (20) could detect 20 fM of non-amplified ssRNA 1 (fig. S6A) and that target detection was also possible on glass fiber paper (fig. S6B). The other components of SHERLOCK are also amenable to freeze-drying: RPA is provided as a lyophilized reagent at ambient temperature, and we previously demonstrated that T7 polymerase tolerates freeze-drying (2). In combination, freeze-drying and paper-spotting the Cas13a detection reaction resulted in comparable levels of sensitive detection of ssRNA 1 as aqueous reactions (fig. S6, C to E). Although paper-spotting and lyophilization slightly reduced the absolute signal of the readout, SHERLOCK (Fig. 2C) could readily detect mock ZIKV virus at concentrations as low as 20 aM (Fig. 2D).

SHERLOCK is also able to detect ZIKV in clinical isolates (serum, urine, or saliva) where titers can be as low as 2×10^3 copies/mL (3.2 aM) (21). ZIKV RNA extracted from patient serum or urine samples and reverse transcribed into cDNA (Fig. 2E) could be detected at concentrations down to 1.25×10^3 copies/mL (2.1 aM), as verified by qPCR (Fig. 2F). Furthermore, the signal from patient samples was predictive of ZIKV RNA copy number and could be used to predict viral load (fig. S6F). To simulate sample detection without nucleic acid purification, we measured detection of ssRNA 1 spiked into human serum, and found that Cas13a could detect RNA in reactions containing as much as 2% serum (fig.

S6G).

Another important epidemiological application for CRISPR-dx is the identification of bacterial pathogens and detection of specific bacterial genes. We targeted the 16S rRNA gene V3 region, where conserved flanking regions allow universal RPA primers to be used across bacterial species and the variable internal region allows for differentiation of species. In a panel of five possible targeting crRNAs for different pathogenic strains and gDNA isolated from *E. coli* and *Pseudomonas aeruginosa* (Fig. 2G), SHERLOCK correctly genotyped strains and showed low cross-reactivity (Fig. 2H). Additionally, we were able to use SHERLOCK to distinguish between clinical isolates of *Klebsiella pneumoniae* with two different resistance genes: *Klebsiella pneumoniae* carbapenemase (KPC) and New Delhi metallo-beta-lactamase 1 (NDM-1) (22) (fig. S7).

To increase the specificity of SHERLOCK, we introduced synthetic mismatches in the crRNA:target duplex that enable LwCas13a to discriminate between targets that differ by a single-base mismatch (fig. S8, A and B). We designed multiple crRNAs with synthetic mismatches in the spacer sequences to detect either the African or American strains of ZIKV (Fig. 3, A and B) and strain 1 or 3 of DENV (Fig. 3, C and D). Synthetic mismatch crRNAs detected their corresponding strains with significantly higher signal (two-tailed Student t test; $p < 0.01$) than the off-target strain, allowing for robust strain discrimination based off single mismatches (Fig. 3, B to D, and fig. S8C). Further characterization revealed that Cas13a detection achieves maximal specificity while maintaining on-target sensitivity when a mutation is in position 3 of the spacer and the synthetic mismatch is in position 5 (figs. S9 and S10).

The ability to detect single-base differences opens the opportunity of using SHERLOCK for rapid human genotyping. We chose five loci spanning a range of health-related single-nucleotide polymorphisms (SNPs) (table S1) and benchmarked SHERLOCK detection using 23andMe genotyping data as the gold standard at these SNPs (23) (Fig. 4A). We collected saliva from four human subjects with diverse genotypes across the loci of interest, and extracted genomic DNA either through column purification or direct heating for five minutes (20). SHERLOCK distinguished alleles with high significance and with enough specificity to infer both homozygous and heterozygous genotypes (Fig. 4B and figs. S11 and S12).

Finally, we sought to determine if SHERLOCK could detect low frequency cancer mutations in cell free (cf) DNA fragments, which is challenging because of the high levels of wild-type DNA in patient blood (24–26). We first found that SHERLOCK could detect ssDNA 1 at attomolar concentrations diluted in a background of genomic DNA (fig. S13A). Next, we found that SHERLOCK was also able to detect sin-

gle nucleotide polymorphism (SNP)-containing alleles (fig. S13, B and C) at levels as low as 0.1% of background DNA, which is in the clinically relevant range. We then demonstrated that SHERLOCK could detect two different cancer mutations, EGFR L858R and BRAF V600E, in mock cfDNA samples with allelic fractions as low as 0.1% (Fig. 4, C to F) (20).

The SHERLOCK platform lends itself to further applications including (i) general RNA/DNA quantitation in lieu of specific qPCR assays, such as TaqMan, (ii) rapid, multiplexed RNA expression detection, and (iii) other sensitive detection applications, such as detection of nucleic acid contamination. Additionally, Cas13a could potentially detect transcripts within biological settings and track allele-specific expression of transcripts or disease-associated mutations in live cells. We have shown that SHERLOCK is a versatile, robust method to detect RNA and DNA, suitable for rapid diagnoses including infectious disease applications and sensitive genotyping. A SHERLOCK paper test can be redesigned and synthesized in a matter of days for as low as \$0.61/test (table S2) with confidence, as almost every crRNA tested resulted in high sensitivity and specificity. These qualities highlight the power of CRISPR-Dx and open new avenues for rapid, robust and sensitive detection of biological molecules.

REFERENCES AND NOTES

1. K. Pardee, A. A. Green, M. K. Takahashi, D. Braff, G. Lambert, J. W. Lee, T. Ferrante, D. Ma, N. Donghia, M. Fan, N. M. Daringer, I. Bosch, D. M. Dudley, D. H. O'Connor, L. Gehrke, J. J. Collins, Rapid, low-cost detection of Zika virus using programmable biomolecular components. *Cell* **165**, 1255–1266 (2016). doi:10.1016/j.cell.2016.04.059 Medline
2. K. Pardee, A. A. Green, T. Ferrante, D. E. Cameron, A. DaleyKeyser, P. Yin, J. J. Collins, Paper-based synthetic gene networks. *Cell* **159**, 940–954 (2014). doi:10.1016/j.cell.2014.10.004 Medline
3. A. A. Green, P. A. Silver, J. J. Collins, P. Yin, Toehold switches: De-novo-designed regulators of gene expression. *Cell* **159**, 925–939 (2014). doi:10.1016/j.cell.2014.10.002 Medline
4. R. M. Kumar, P. Cahan, A. K. Shalek, R. Satija, A. J. DaleyKeyser, H. Li, J. Zhang, K. Pardee, D. Gennert, J. J. Trombetta, T. C. Ferrante, A. Regev, G. Q. Daley, J. J. Collins, Deconstructing transcriptional heterogeneity in pluripotent stem cells. *Nature* **516**, 56–61 (2014). doi:10.1038/nature13920 Medline
5. M. Urdea, L. A. Penny, S. S. Olmsted, M. Y. Giovanni, P. Kaspar, A. Shepherd, P. Wilson, C. A. Dahl, S. Buchsbaum, G. Moeller, D. C. Hay Burgess, Requirements for high impact diagnostics in the developing world. *Nature* **444** (suppl. 1), 73–79 (2006). doi:10.1038/nature05448 Medline
6. Y. Du, A. Pothukuchy, J. D. Gollihar, A. Nourani, B. Li, A. D. Ellington, Coupling sensitive nucleic acid amplification with commercial pregnancy test strips. *Angew. Chem. Int. Ed.* **56**, 992–996 (2017). doi:10.1002/anie.201609108 Medline
7. B. Zetsche, J. S. Gootenberg, O. O. Abudayyeh, I. M. Slaymaker, K. S. Makarova, P. Essletzbichler, S. E. Volz, J. Joung, J. van der Oost, A. Regev, E. V. Koonin, F. Zhang, Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. *Cell* **163**, 759–771 (2015). doi:10.1016/j.cell.2015.09.038 Medline
8. S. Shmakov, A. Smargon, D. Scott, D. Cox, N. Pyzocha, W. Yan, O. O. Abudayyeh, J. S. Gootenberg, K. S. Makarova, Y. I. Wolf, K. Severinov, F. Zhang, E. V. Koonin, Diversity and evolution of class 2 CRISPR-Cas systems. *Nat. Rev. Microbiol.* **15**, 169–182 (2017). doi:10.1038/nrmicro.2016.184 Medline
9. S. Shmakov, O. O. Abudayyeh, K. S. Makarova, Y. I. Wolf, J. S. Gootenberg, E. Semenova, L. Minakhin, J. Joung, S. Konermann, K. Severinov, F. Zhang, E. V. Koonin, Discovery and functional characterization of diverse class 2 CRISPR-Cas systems. *Mol. Cell* **60**, 385–397 (2015). doi:10.1016/j.molcel.2015.10.008 Medline
10. O. O. Abudayyeh, J. S. Gootenberg, S. Konermann, J. Joung, I. M. Slaymaker, D. B. T. Cox, S. Shmakov, K. S. Makarova, E. Semenova, L. Minakhin, K. Severinov, A. Regev, E. S. Lander, E. V. Koonin, F. Zhang, C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. *Science* **353**, aaf5573 (2016). doi:10.1126/science.aaf5573 Medline
11. A. A. Smargon, D. B. T. Cox, N. K. Pyzocha, K. Zheng, I. M. Slaymaker, J. S. Gootenberg, O. A. Abudayyeh, P. Essletzbichler, S. Shmakov, K. S. Makarova, E. V. Koonin, F. Zhang, Cas13b is a type VI-B CRISPR-associated RNA-guided RNase differentially regulated by accessory proteins Csx27 and Csx28. *Mol. Cell* **65**, 618–630.e7 (2017). doi:10.1016/j.molcel.2016.12.023 Medline
12. A. East-Seletsky, M. R. O'Connell, S. C. Knight, D. Burstein, J. H. D. Cate, R. Tjian, J. A. Doudna, Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection. *Nature* **538**, 270–273 (2016). doi:10.1038/nature19802 Medline
13. C. Ohtaka-Maruyama, K. Nakajima, A. Pierani, N. Maeda, Editorial: Mechanisms of neuronal migration during corticogenesis. *Front. Neurosci.* **10**, 172 (2016). doi:10.3389/fnins.2016.00172 Medline
14. R. Emmadi, J. B. Boonyaratankornkit, R. Selvarangan, V. Shyamala, B. L. Zimmer, L. Williams, B. Bryant, T. Schutzbank, M. M. Schoonmaker, J. A. Amos Wilson, L. Hall, P. Pancholi, K. Bernard, Molecular methods and platforms for infectious diseases testing: a review of FDA-approved and cleared assays. *J. Mol. Diagn.* **13**, 583–604 (2011). doi:10.1016/j.jmoldx.2011.05.011 Medline
15. L. Song, D. Shan, M. Zhao, B. A. Pink, K. A. Minnehan, L. York, M. Gardel, S. Sullivan, A. F. Phillips, R. B. Hayman, D. R. Walt, D. C. Duffy, Direct detection of bacterial genomic DNA at sub-femtomolar concentrations using single molecule arrays. *Anal. Chem.* **85**, 1932–1939 (2013). doi:10.1021/ac303426h Medline
16. J. M. Barletta, D. C. Edelman, N. T. Constantine, Lowering the detection limits of HIV-1 viral load using real-time immuno-PCR for HIV-1 p24 antigen. *Am. J. Clin. Pathol.* **122**, 20–27 (2004). doi:10.1309/529T2WDNEB6X8VUJN Medline
17. J. Compton, Nucleic acid sequence-based amplification. *Nature* **350**, 91–92 (1991). doi:10.1038/350091a0 Medline
18. O. Piepenburg, C. H. Williams, D. L. Stemple, N. A. Armes, DNA detection using recombination proteins. *PLOS Biol.* **4**, e204 (2006). doi:10.1371/journal.pbio.0040204 Medline
19. W. Dejnirattisai, P. Supasa, W. Wongwiwat, A. Rouvinski, G. Barba-Spaeth, T. Duangchinda, A. Sakuntabhai, V.-M. Cao-Lormeau, P. Malasit, F. A. Rey, J. Mongkolsapaya, G. R. Screaton, Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus. *Nat. Immunol.* **17**, 1102–1108 (2016). doi:10.1038/ni.3515 Medline
20. Materials and methods are available as supplementary materials.
21. G. Paz-Bailey, E. S. Rosenberg, K. Doyle, J. Munoz-Jordan, G. A. Santiago, L. Klein, J. Perez-Padilla, F. A. Medina, S. H. Waterman, C. G. Gubern, L. I. Alvarado, T. M. Sharp, Persistence of Zika virus in body fluids - preliminary report. *N. Engl. J. Med.* NEJMoa1613108 (2017). doi:10.1056/NEJMoa1613108 Medline
22. N. Gupta, B. M. Limbago, J. B. Patel, A. J. Kallen, Carbapenem-resistant *Enterobacteriaceae*: Epidemiology and prevention. *Clin. Infect. Dis.* **53**, 60–67 (2011). doi:10.1093/cid/cir202 Medline
23. N. Eriksson, J. M. Macpherson, J. Y. Tung, L. S. Hon, B. Naughton, S. Saxonov, L. Avey, A. Wojcicki, I. Pe'er, J. Mountain, Web-based, participant-driven studies yield novel genetic associations for common traits. *PLOS Genet.* **6**, e1000993 (2010). doi:10.1371/journal.pgen.1000993 Medline
24. Z. Qin, V. A. Ljubimov, C. Zhou, Y. Tong, J. Liang, Cell-free circulating tumor DNA in cancer. *Chin. J. Cancer* **35**, 36 (2016). doi:10.1186/s40880-016-0092-4 Medline
25. C. Bettgowda, M. Sausen, R. J. Leary, I. Kinde, Y. Wang, N. Agrawal, B. R. Bartlett, H. Wang, B. Lubber, R. M. Alani, E. S. Antonarakis, N. S. Azad, A. Bardelli, H. Brem, J. L. Cameron, C. C. Lee, L. A. Fecher, G. L. Gallia, P. Gibbs, D. Le, R. L. Giuntoli, M. Goggins, M. D. Hogarty, M. Holdhoff, S.-M. Hong, Y. Jiao, H. H. Juhl, J. J. Kim, G. Siravegna, D. A. Laheru, C. Lauricella, M. Lim, E. J. Lipson, S. K. N. Marie, G. J. Netto, K. S. Oliner, A. Olivi, L. Olsson, G. J. Riggins, A. Sartore-Bianchi, K. Schmidt, M. Shih, S. M. Oba-Shinjo, S. Siena, D. Theodorescu, J. Tie,

- T. T. Harkins, S. Veronese, T.-L. Wang, J. D. Weingart, C. L. Wolfgang, L. D. Wood, D. Xing, R. H. Hruban, J. Wu, P. J. Allen, C. M. Schmidt, M. A. Choti, V. E. Velculescu, K. W. Kinzler, B. Vogelstein, N. Papadopoulos, L. A. Diaz Jr., Detection of circulating tumor DNA in early- and late-stage human malignancies. *Sci. Transl. Med.* **6**, 224ra24 (2014). doi:10.1126/scitranslmed.3007094 Medline
26. A. M. Newman, S. V. Bratman, J. To, J. F. Wynne, N. C. W. Eclow, L. A. Modlin, C. L. Liu, J. W. Neal, H. A. Wakelee, R. E. Merritt, J. B. Shrager, B. W. Loo Jr., A. A. Alizadeh, M. Diehn, An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. *Nat. Med.* **20**, 548–554 (2014). doi:10.1038/nm.3519 Medline
27. T. Notomi, H. Okayama, H. Masubuchi, T. Yonekawa, K. Watanabe, N. Amino, T. Hase, Loop-mediated isothermal amplification of DNA. *Nucleic Acids Res.* **28**, e63 (2000). doi:10.1093/nar/28.12.e63 Medline
28. G. T. Walker, M. S. Fraiser, J. L. Schram, M. C. Little, J. G. Nadeau, D. P. Malinowski, Strand displacement amplification—an isothermal, in vitro DNA amplification technique. *Nucleic Acids Res.* **20**, 1691–1696 (1992). doi:10.1093/nar/20.7.1691 Medline
29. M. Vincent, Y. Xu, H. Kong, Helicase-dependent isothermal DNA amplification. *EMBO Rep.* **5**, 795–800 (2004). doi:10.1038/sj.embor.7400200 Medline
30. J. Van Ness, L. K. Van Ness, D. J. Galas, Isothermal reactions for the amplification of oligonucleotides. *Proc. Natl. Acad. Sci. U.S.A.* **100**, 4504–4509 (2003). doi:10.1073/pnas.073081100 Medline
31. A. J. Das, A. Wahi, I. Kothari, R. Raskar, Ultra-portable, wireless smartphone spectrometer for rapid, non-destructive testing of fruit ripeness. *Sci. Rep.* **6**, 32504 (2016). doi:10.1038/srep32504 Medline
32. J. Ye, G. Coulouris, I. Zaretskaya, I. Cutcutache, S. Rozen, T. L. Madden, Primer-BLAST: A tool to design target-specific primers for polymerase chain reaction. *BMC Bioinformatics* **13**, 134 (2012). doi:10.1186/1471-2105-13-134 Medline

ACKNOWLEDGMENTS

Acknowledgments: We thank F. Chen, V. Rusu, R. Gupta, D. Daniels, C. Garvie, I. Finkelstein, V. Adalsteinsson, A. Das, E.S. Lander, R. Macrae, and R. Belliveau for discussions and support. Human genotyping data was collected with informed consent by the subjects and in consent with the guidelines of the approved MIT IRB protocol IRB-4062. O.A.A. is supported by a Paul and Daisy Soros Fellowship and National Defense Science and Engineering Fellowship. J.S.G. is supported by a D.O.E. Computational Science Graduate Fellowship. R.P.B., J.L., and D.T.H. are supported by the NIH through NIAID (R01AI117043). A.D. is supported by an NSF Graduate Research Fellowship and a Air Force Office of Scientific Research grant (FA9550-14-1-0060). Zika work was partially funded by Marc and Lynne Benioff to P.C.S. and antibiotic resistance work was partially funded by Josh and Anita Bekenstein to D.T.H. A.R. is supported by the Howard Hughes Medical Institute. F.Z. is a New York Stem Cell Foundation-Robertson Investigator. F.Z. is supported by the NIH through NIMH (5DP1-MH100706 and 1R01-MH110049), NSF, Howard Hughes Medical Institute, the New York Stem Cell, Simons, Paul G. Allen Family, and Vallee Foundations; and James and Patricia Poitras, Robert Metcalfe, and David Cheng. A.R. is a member of the Scientific Advisory Board for ThermoFisher Scientific. J.S.G., O.O.A, R.P.B., A.R., E.V.K., D.T.H., P.C.S., J.J.C and F.Z. have filed patent applications relating to the work in this manuscript, including J.S.G., O.O.A, E.V.K. and F.Z on International application no. PCT/US2016/038258 filed June 18, 2015 (CRISPR-C2c2 systems and uses thereof); J.S.G., O.O.A, and F.Z on US provisional patent application no. 62/351,662 filed June 17, 2016 (CRISPR-C2c2 systems and diagnostic uses thereof); J.S.G., O.O.A, J.J.C and F.Z on US provisional patent application no. 62/432,553 filed December 9, 2016 (SHERLOCK diagnostic); J.S.G., O.O.A, P.C.S., J.J.C and F.Z on US provisional patent application no. 62/471,917 filed March 15, 2017 (viral application of SHERLOCK); J.S.G., O.O.A, A.R., J.J.C and F.Z on US provisional patent application no. 62/471,931 filed March 15, 2017 (mutation detection with SHERLOCK); J.S.G., O.O.A, R.P.B., D.T.H., J.J.C and F.Z on US provisional patent application no. 62/471,936 filed March 15, 2017 (bacterial applications of SHERLOCK); and J.S.G., O.O.A, J.J.C and F.Z on US provisional patent application no. 62/471,940 filed March 15, 2017 (devices), each relating to CRISPR-C2c2 systems, specific uses and improved uses thereof for diagnostic application filed by Broad, Harvard, MGH, MIT and NIH. Cas13a/C2c2 expression plasmids are available from Addgene under UBMTA.

SUPPLEMENTARY MATERIALS

www.sciencemag.org/cgi/content/full/science.aam9321/DC1
Materials and Methods
Supplementary Text
Figs. S1 to S13
Tables S1 to S7
References (27–32)

6 February 2017; accepted 5 April 2017
Published online 13 April 2017
10.1126/science.aam9321




Fig. 1. SHERLOCK is capable of single-molecule nucleic acid detection. (A) Schematic of SHERLOCK. (B) Schematic of ssRNA target detected via the Cas13a collateral detection. The target site is highlighted in blue. (C) Cas13a detection of RNA with RPA amplification (SHERLOCK) can detect ssRNA target at concentrations down to ~2 aM, more sensitive than Cas13a alone. (n=4 technical replicates; bars represent mean \pm s.e.m.) (D) SHERLOCK is also capable of single-molecule DNA detection. (n=4 technical replicates; bars represent mean \pm s.e.m.)




Fig. 2. Cas13a detection can be used to sense viral and bacterial pathogens. (A) Schematic of ZIKV RNA detection by SHERLOCK. (B) SHERLOCK is capable of highly sensitive detection of the ZIKV lentiviral particles. (n=4 technical replicates, two-tailed Student t test; ****, $p < 0.0001$; bars represent mean \pm s.e.m.; n.d., not detected) (C) Schematic of ZIKV RNA detection with freeze-dried Cas13a on paper (D) Paper-based SHERLOCK is capable of highly sensitive detection of ZIKV lentiviral particles. (n=4 technical replicates, two-tailed Student t test; **, $p < 0.01$; ****, $p < 0.0001$; bars represent mean \pm s.e.m.) (E) Schematic of SHERLOCK detection of ZIKV RNA isolated from human clinical samples. (F) SHERLOCK is capable of highly sensitive detection of human ZIKV-positive serum (S) or urine (U) samples. Approximate concentrations of ZIKV RNA shown were determined by qPCR. (n=4 technical replicates, two-tailed Student t test; ****, $p < 0.0001$; bars represent mean \pm s.e.m.; n.d., not detected) (G) Schematic of using SHERLOCK to distinguish bacterial strains using a universal 16S rRNA gene V3 RPA primer set. (H) SHERLOCK achieves sensitive and specific detection of *E. coli* or *P. aeruginosa* gDNA. (n=4 technical replicates, two-tailed Student t test; *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$; bars represent mean \pm s.e.m.). Ec, *Escherichia coli*; Kp, *Klebsiella pneumoniae*; Pa, *Pseudomonas aeruginosa*; Mt, *Mycobacterium tuberculosis*; Sa, *Staphylococcus aureus*.




Fig. 3. Cas13a detection can discriminate between similar viral strains. (A) Schematic of ZIKV strain target regions and the crRNA sequences used for detection. SNPs in the target are highlighted red or blue and synthetic mismatches in the guide sequence are colored red. (B) Highly specific detection of strain SNPs allows for the differentiation of ZIKV African versus American RNA targets using Cas13a. (n=2 technical replicates, two-tailed Student t test; **, p < 0.01; ***, p < 0.001; bars represent mean ± s.e.m.) (C) Schematic of DENV strain target regions and the crRNA sequences used for detection. SNPs in the target are highlighted red or blue and synthetic mismatches in the guide sequence are colored red. (D) Highly specific detection of strain SNPs allows for the differentiation of DENV strain 1 versus strain 3 RNA targets using Cas13a. (n=2 technical replicates, two-tailed Student t test; *, p < 0.05; **, p < 0.01; ***, p < 0.001; bars represent mean ± s.e.m.)




Fig. 4. SHERLOCK can discriminate SNPs for human genotyping and cell-free allele DNA detection. (A) Circos plot showing location of human SNPs detected with SHERLOCK. (B) SHERLOCK can correctly genotype four different individuals at four different SNP sites in the human genome. The genotypes for each individual and identities of allele-sensing crRNAs are annotated below each plot. (n=4 technical replicates, two-tailed Student t test; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; bars represent mean \pm s.e.m.) (C) Schematic of cell-free DNA detection of cancer mutations using SHERLOCK. (D) Sequences of two genomic loci assayed for cancer mutations in cell-free DNA. Shown are the target genomic sequence with the SNP highlighted in blue and the mutant/wild-type sensing crRNA sequences with synthetic mismatches colored in red. (E and F) Cas13a can detect the mutant minor allele in mock cell-free DNA samples for the EGFR L858R (E) or the BRAF V600E (F) minor allele. (n=4 technical replicates, two-tailed Student t test; *, p < 0.05; **, p < 0.01; ****, p < 0.0001; bars represent mean \pm s.e.m.)



Nucleic acid detection with CRISPR-Cas13a/C2c2

Jonathan S. Gootenberg, Omar O. Abudayyeh, Jeong Wook Lee, Patrick Essletzbichler, Aaron J. Dy, Julia Joung, Vanessa Verdine, Nina Donghia, Nichole M. Daringer, Catherine A. Freije, Cameron Myhrvold, Roby P. Bhattacharyya, Jonathan Livny, Aviv Regev, Eugene V. Koonin, Deborah T. Hung, Pardis C. Sabeti, James J. Collins and Feng Zhang (April 13, 2017)
published online April 13, 2017

Editor's Summary

This copy is for your personal, non-commercial use only.

- Article Tools** Visit the online version of this article to access the personalization and article tools:
<http://science.sciencemag.org/content/early/2017/04/12/science.aam9321>
- Permissions** Obtain information about reproducing this article:
<http://www.sciencemag.org/about/permissions.dtl>

Science (print ISSN 0036-8075; online ISSN 1095-9203) is published weekly, except the last week in December, by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. Copyright 2016 by the American Association for the Advancement of Science; all rights reserved. The title *Science* is a registered trademark of AAAS.